Lupin Limited reported a 27% year-on-year increase in standalone net profit after tax (PAT) to ₹27,146 million for the quarter ended June 30, 2026, driven by strong revenue growth across its core pharmaceutical business. The company’s consolidated revenue from operations surged 32% to ₹82,769 million, while consolidated PAT rose 16% to ₹14,170 million. These results reflect sustained momentum in the US generics market and effective cost management, positioning the firm for continued expansion in FY26.

The Board of Directors, chaired by Managing Director Nilesh D. Gupta, approved the unaudited standalone and consolidated financial results at a meeting held on August 06, 2026. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, Deloitte Haskins & Sells Chartered Accountants LLP, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

Standalone sales/income from operations jumped 27% to ₹71,125 million from ₹56,054 million in Q1FY25. Total revenue from operations reached ₹71,719 million. On a consolidated basis, total income stood at ₹84,072 million, compared to ₹63,474 million in the corresponding quarter last year. The Pharmaceuticals segment contributed ₹82,344 million to consolidated revenue, accounting for the vast majority of the group’s top-line growth.

The standalone basic earnings per share (EPS) increased to ₹59.37 from ₹46.60 in the previous year’s quarter. Consolidated basic EPS rose to ₹30.95 from ₹26.70. Other income for the standalone entity was ₹1,025 million, while consolidated other income stood at ₹1,303 million.

Key Developments and Segment Analysis

The Pharmaceuticals segment generated a result before tax and exceptional items of ₹20,606 million in the consolidated books, up significantly from ₹14,578 million in Q1FY25. This growth underscores the segment’s dominance in driving profitability. The 'Others' segment reported a loss of ₹432 million, consistent with its historical pattern of lower margins.

During the quarter, Lupin concluded the acquisition of wholly-owned subsidiary VISUfarma B.V., Netherlands, through Nanomi B.V. on April 01, 2026. The total consideration was ₹20,903 million (Euro 192.8 million). The fair value of intangibles acquired was ₹15,971 million, with goodwill provisionally accounted at ₹6,030 million based on an independent valuer’s report. Additionally, 53,425 equity shares were allotted upon the exercise of vested stock options under the Lupin Employees Stock Option Plans, increasing paid-up capital by ₹0.1 million and securities premium by ₹76.9 million.

What the Numbers Show

A notable divergence exists between standalone and consolidated profitability metrics. While standalone PAT grew by 27%, consolidated PAT growth was more modest at 16%. This gap is primarily attributable to higher tax expenses and integration costs associated with recent acquisitions, including VISUfarma. Furthermore, the group recognized an impairment charge of ₹879 million during the quarter related to certain capital work-in-progress and intangible assets under development. Despite these headwinds, the core pharmaceutical business demonstrated resilience, with revenue growth outpacing expense inflation, indicating strong operational leverage in key markets.

Lupin Ltd. recorded a notable block trade on the National Stock Exchange (NSE), with the transaction valued at ₹29.03 crores. The deal involved approximately 1,21,534 shares, executed at a price of ₹2388.30 per share.

Block Trade Details

The following table summarizes the key parameters of the block trade:

Block trades are large, privately negotiated securities transactions that are executed outside of the open market to minimize the impact on the stock's prevailing price. Such transactions are generally associated with institutional investors or significant stakeholders, and their occurrence on major exchanges like the NSE is closely monitored by market participants.